MétaCan
Menu
Back to cohort
Record W3213060608 · doi:10.1212/wnl.0000000000012868

Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary

2021· article· en· W3213060608 on OpenAlexfundno aff

Bibliographic record

VenueNeurology · 2021
Typearticle
Languageen
FieldMedicine
TopicParkinson's Disease Mechanisms and Treatments
Canadian institutionsnot available
FundersNational Institute on AgingCanadian Institutes of Health ResearchAvid RadiopharmaceuticalsAlberta Children's Hospital Research InstituteParkinsonfondenNational Institutes of HealthAmneal PharmaceuticalsMerz PharmaceuticalsMitsubishi Tanabe Pharma CorporationDavis Phinney FoundationAcorda TherapeuticsUniversity of CambridgeFondation DesmarestEli Lilly and CompanyAdamas PharmaceuticalsSupernus PharmaceuticalsCivitas TherapeuticsAllerganRush UniversityF. Hoffmann-La RocheSarepta TherapeuticsAgency for Healthcare Research and QualityNorthwestern UniversityNeurocrine BiosciencesACADIA PharmaceuticalsKaiser PermanenteUS WorldMedsMichael J. Fox Foundation for Parkinson's ResearchJazz PharmaceuticalsParkinson's FoundationBritannia PharmaceuticalsWeston Brain InstituteIpsenUCB USDystonia Medical Research FoundationH. Lundbeck A/SSunovionEVER Neuro PharmaAmadysSanofiRevanceBoston Scientific CorporationBiogenAgence Nationale de la RechercheDemensförbundetFlorida Department of HealthNational Parkinson FoundationTeva Pharmaceutical IndustriesCleveland ClinicAstraZenecaInternational Parkinson and Movement Disorder SocietyPfizerAxial BiotherapeuticsPatient-Centered Outcomes Research InstituteSun PharmaEuropean Academy of NeurologyAmerican Brain FoundationDenali Therapeutics
KeywordsLevodopaEntacaponeDopamineGuidelineDopaminergicDopamine agonistDiseaseRopinirole

Abstract

fetched live from OpenAlex

BACKGROUND AND OBJECTIVES: To review the current evidence on the options available for initiating dopaminergic treatment of motor symptoms in early-stage Parkinson disease and provide recommendations to clinicians. METHODS: A multidisciplinary panel developed practice recommendations, integrating findings from a systematic review and following an Institute of Medicine-compliant process to ensure transparency and patient engagement. Recommendations were supported by structured rationales, integrating evidence from the systematic review, related evidence, principles of care, and inferences from evidence. RESULTS: Initial treatment with levodopa provides superior motor benefit compared to treatment with dopamine agonists, whereas levodopa is more likely than dopamine agonists to cause dyskinesia. The comparison of different formulations of dopamine agonists yielded little evidence that any one formulation or method of administration is superior. Long-acting forms of levodopa and levodopa with entacapone do not appear to differ in efficacy from immediate-release levodopa for motor symptoms in early disease. There is a higher risk of impulse control disorders associated with the use of dopamine agonists than levodopa. Recommendations on initial therapy for motor symptoms are provided to assist the clinician and patient in choosing between treatment options and to guide counseling, prescribing, and monitoring of efficacy and safety.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.715
Threshold uncertainty score0.721

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.016
GPT teacher head0.293
Teacher spread0.277 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations184
Published2021
Admission routes1
Has abstractyes

Explore more

Same venueNeurologySame topicParkinson's Disease Mechanisms and TreatmentsFrench-language works237,207